Research graph
References from Identifying the patient at risk for post‐transplant lymphoproliferative disorder. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1034/j.1399-3062.2001.003002060.x · Admitted local publication
10.1038/335256a0
10.1038/335256a0 · External reference
10.1093/infdis/152.5.876
10.1093/infdis/152.5.876 · External reference
Epstein–Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4.
10.1128/jvi.65.2.976-980.1991 · 1991 · External reference
10.1097/00007890-199001000-00028
10.1097/00007890-199001000-00028 · External reference
10.1099/0022-1317-77-6-1169
10.1099/0022-1317-77-6-1169 · External reference
10.1097/00007890-199307000-00016
10.1097/00007890-199307000-00016 · External reference
Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for post‐transplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
1995 · External reference
10.1056/nejm199012203232502
10.1056/nejm199012203232502 · External reference
10.1093/clinids/20.5.1346
10.1093/clinids/20.5.1346 · External reference
10.1097/00007890-199910150-00017
10.1097/00007890-199910150-00017 · External reference
10.1097/00007890-199711270-00011
10.1097/00007890-199711270-00011 · External reference
10.1097/00007890-200003150-00039
10.1097/00007890-200003150-00039 · External reference
The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
2000 · External reference
Risk factors for developing EBV‐related B cell lymphoproliferative disorders (BLPD) after non‐HLA‐identical BMT in children.
1996 · External reference
10.1099/0022-1317-75-1-85
10.1099/0022-1317-75-1-85 · External reference
10.1200/jco.1998.16.6.2052
10.1200/jco.1998.16.6.2052 · External reference
10.1097/00007890-200003150-00027
10.1097/00007890-200003150-00027 · External reference
10.1016/s0140-6736(05)80084-4
10.1016/s0140-6736(05)80084-4 · External reference
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A – prednisone immunosuppression.
1988 · External reference
Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine‐based immunosuppression.
1991 · External reference
10.1378/chest.116.5.1273
10.1378/chest.116.5.1273 · External reference
10.1093/ajcp/92.2.177
10.1093/ajcp/92.2.177 · External reference
10.1097/00007890-199904150-00021
10.1097/00007890-199904150-00021 · External reference
10.1016/s1072-7515(98)00083-0
10.1016/s1072-7515(98)00083-0 · External reference
Epstein–Barr virus lymphoproliferation after bone marrow transplantation.
10.1182/blood.v72.2.520.520 · 1988 · External reference
Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation.
10.1182/blood.v71.5.1234.1234 · 1988 · External reference
10.1038/sj.bmt.1701554
10.1038/sj.bmt.1701554 · External reference
The development of cellular immunity to Epstein–Barr virus after allogeneic bone marrow transplantation.
10.1182/blood.v87.6.2594.bloodjournal8762594 · 1996 · External reference
10.1056/nejm198909213211203
10.1056/nejm198909213211203 · External reference
Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus‐induced lymphoma in allogeneic transplant recipients.
10.1182/blood.v92.5.1549.417k32_1549_1555 · 1998 · External reference
10.3109/10428199909145954
10.3109/10428199909145954 · External reference
10.1007/s002810050044
10.1007/s002810050044 · External reference
10.1172/jci116523
10.1172/jci116523 · External reference
10.1034/j.1399-0012.1999.130405.x
10.1034/j.1399-0012.1999.130405.x · External reference
10.1097/00007890-199903270-00015
10.1097/00007890-199903270-00015 · External reference
10.1034/j.1399-0012.1999.t01-2-130106.x
10.1034/j.1399-0012.1999.t01-2-130106.x · External reference
10.1016/s0002-9440(10)65119-x
10.1016/s0002-9440(10)65119-x · External reference
10.1007/s002810050045
10.1007/s002810050045 · External reference
10.1097/00007890-200004271-01077
10.1097/00007890-200004271-01077 · External reference
10.1097/00007890-200004271-00265
10.1097/00007890-200004271-00265 · External reference
10.1086/314883
10.1086/314883 · External reference
10.1038/sj.leu.2401390
10.1038/sj.leu.2401390 · External reference
10.1086/514142
10.1086/514142 · External reference
Malignancy and posttransplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study Group (NAPRTCS).
1998 · External reference
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders.
10.1182/blood.v87.10.4296.bloodjournal87104296 · 1996 · External reference
10.1002/hep.510300314
10.1002/hep.510300314 · External reference
10.1097/00007890-199912270-00006
10.1097/00007890-199912270-00006 · External reference
Malignant lymphomas in transplanted patients.
1969 · External reference
10.1016/s0140-6736(79)92440-1
10.1016/s0140-6736(79)92440-1 · External reference
10.1097/00007890-199401000-00017
10.1097/00007890-199401000-00017 · External reference
10.1097/00007890-199910270-00024
10.1097/00007890-199910270-00024 · External reference
10.1097/00007890-199502270-00015
10.1097/00007890-199502270-00015 · External reference
10.1016/s0272-6386(99)70358-6
10.1016/s0272-6386(99)70358-6 · External reference
10.1097/00007890-199806150-00007
10.1097/00007890-199806150-00007 · External reference
10.1097/00007890-199908150-00011
10.1097/00007890-199908150-00011 · External reference
10.1097/00007890-199808270-00016
10.1097/00007890-199808270-00016 · External reference
10.1007/s002810050040
10.1007/s002810050040 · External reference
Fulminant Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders following OKT3 therapy.
10.1111/j.1399-0012.1992.tb00580.x · 1992 · External reference
10.2165/00063030-199911050-00005
10.2165/00063030-199911050-00005 · External reference
10.1034/j.1399-3046.1999.00039.x
10.1034/j.1399-3046.1999.00039.x · External reference
10.1007/s002810050046
10.1007/s002810050046 · External reference
10.1034/j.1399-3046.1999.00066.x
10.1034/j.1399-3046.1999.00066.x · External reference
10.1093/infdis/166.5.986
10.1093/infdis/166.5.986 · External reference
Evidence for restricted Epstein–Barr virus latent gene expression and anti‐EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders.
10.1182/blood.v81.5.1393.1393 · 1993 · External reference
Increased levels of circulating Epstein–Barr virus (EBV)‐infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid‐organ transplant recipients.
10.1182/blood.v84.3.972.972 · 1994 · External reference
10.1002/hep.1840200419
10.1002/hep.1840200419 · External reference
10.1034/j.1399-3062.2001.003002097.x
10.1034/j.1399-3062.2001.003002097.x · External reference
10.1097/00007890-199812270-00006
10.1097/00007890-199812270-00006 · External reference
